Age-based outcomes and patterns of care of patients with metastatic pancreatic cancer: An updated comparative analysis from Fox Chase Cancer Center.

Key Points

• This research evaluates how age impacts treatment patterns and overall survival in metastatic pancreatic cancer patients.
• Reviewed charts of 730 patients with metastatic pancreatic cancer from 2012-2022
• Used descriptive statistics to summarize demographics and treatment
• Estimated overall survival using Kaplan-Meier curves
• Applied multivariable Cox proportional hazards models to adjust for confounders
• 304 younger adults (median age 59) and 426 older adults (median age 73) analyzed
• No significant difference in chemotherapy likelihood (78% OA, 81% YA)
• Younger adults more likely to receive FOLFIRINOX (32% YA vs 13.6% OA)
• Overall survival was similar between age groups with 10.7 mo (YA) vs 8.7 mo (OA)